Philogen SpA (IT:PHIL)
:PHIL
Want to see IT:PHIL full AI Analyst Report?
Top Page
Philogen SpA
(PHIL)
Select Model
Select Model
Rating:67Neutral
Price Target:
€21.50
▼(-7.33% Downside)
Action:DowngradedDate:04/13/26
Strong recent financial performance (high profitability, strong cash generation, and low leverage) supports the score, but it is meaningfully offset by weak technicals (below major moving averages with negative MACD) and uncertain valuation signals due to a negative P/E and no dividend yield data.
Positive Factors
Conservative balance sheet
Low debt (10.9M vs equity 373.9M in 2025) and a large rise in total assets give Philogen financial flexibility. This conservative capitalization reduces near-term refinancing risk and supports multi-stage R&D funding and partnership optionality over the next several quarters.
Negative Factors
Historical profitability volatility
Prior multi-year losses and negative cash flows highlight volatility in underlying business performance. The recent profitable year may reflect timing of milestones or contracts; recurrence of loss-making periods would pressure cash and investor confidence within months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low debt (10.9M vs equity 373.9M in 2025) and a large rise in total assets give Philogen financial flexibility. This conservative capitalization reduces near-term refinancing risk and supports multi-stage R&D funding and partnership optionality over the next several quarters.
Read all positive factors
Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€633.11M
Dividend YieldN/A
Average Volume (3M)19.28K
Price to Earnings (P/E)4.1
Beta (1Y)-0.19
Revenue Growth324.79%
EPS Growth407.11%
CountryIT
Employees174
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)1.16
Shares Outstanding29,242,860
10 Day Avg. Volume19,753
30 Day Avg. Volume19,281
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.51
Price to Sales (P/S)2.99
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.00Price Target Upside12.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€54.07M
Philogen SpA Business Overview & Revenue Model
Company Description
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma a...
How the Company Makes Money
null...
Philogen SpA Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.86M | 314.32M | 74.00M | 23.13M | 23.71M | 2.50M |
| Gross Profit | 43.76M | 271.84M | 54.42M | 5.67M | 10.53M | -8.14M |
| EBITDA | 43.70M | 255.84M | 44.75M | -2.05M | -1.17M | -12.98M |
| Net Income | 45.91M | 229.68M | 45.29M | -6.16M | -5.38M | -15.72M |
Balance Sheet | ||||||
| Total Assets | 159.35M | 437.33M | 168.45M | 119.27M | 125.83M | 132.75M |
| Cash, Cash Equivalents and Short-Term Investments | 100.02M | 379.22M | 113.73M | 75.34M | 86.20M | 101.68M |
| Total Debt | 11.50M | 10.88M | 11.51M | 14.91M | 15.76M | 16.49M |
| Total Liabilities | 33.54M | 63.46M | 29.80M | 28.68M | 27.91M | 27.67M |
| Stockholders Equity | 125.81M | 373.86M | 138.66M | 90.59M | 97.92M | 105.09M |
Cash Flow | ||||||
| Free Cash Flow | 37.15M | 268.05M | 38.67M | -10.37M | -9.15M | -25.85M |
| Operating Cash Flow | 39.55M | 271.44M | 40.84M | -4.82M | -4.94M | -19.03M |
| Investing Cash Flow | -36.03M | -171.82M | -22.28M | 159.00K | 24.20M | -47.77M |
| Financing Cash Flow | -4.80M | -2.99M | -3.78M | -4.17M | -3.78M | 63.05M |
Philogen SpA Technical Analysis
Negative
23.20
Price Trends
21.67
Negative
22.15
Negative
22.56
Negative
Market Momentum
-0.35
Positive
47.94
Neutral
50.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Negative. The current price of 23.2 is above the 20-day moving average (MA) of 21.70, above the 50-day MA of 21.67, and above the 200-day MA of 22.56, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 47.94 is Neutral, neither overbought nor oversold. The STOCH value of 50.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHIL.
Philogen SpA Peers Comparison
UnderperformOutperform
Sector (55)
IT:PHIL
Philogen SpA
21.65
-0.15
-0.69%
IT:PHN
PharmaNutra SpA
78.80
24.60
45.39%
IT:GHC
Garofalo Health Care S.P.A.
5.12
-0.01
-0.27%
IT:ARBS
Arterra Bioscience SpA
3.08
0.84
37.50%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.15
0.09
8.49%
IT:SVS
Svas Biosana S.p.A.
9.10
1.73
23.47%
Philogen SpA Corporate Events
Philogen Expands Treasury Stock Position as Share Buyback Programme Progresses
Apr 13, 2026
Philogen has continued its share buyback programme on Euronext Milan, repurchasing 6,729 shares between 6 and 10 April 2026, equal to 0.0166% of its share capital, for a total outlay of about €136,600 at an average price of roughly €20...
Philogen Publishes 2025 Financial and Governance Reports Ahead of April 2026 Shareholders’ Meeting
Apr 8, 2026
Philogen S.p.A., a biotechnology group specializing in targeted anticancer therapies and other potential applications for severe diseases, leverages proprietary ligand-isolation technologies and a broad patent portfolio to develop drugs that conce...
Philogen Discloses March Share Purchases by Mediobanca on Italian Market
Apr 8, 2026
Philogen S.p.A. disclosed that Mediobanca S.p.A., acting under an unspecified engagement, carried out a series of share purchase transactions in Philogen stock on the Italian regulated market in early March 2026. Over the period from 2 to 6 March,...
Philogen Publishes Documentation Ahead of April 2026 Shareholders’ Meeting
Mar 30, 2026
Philogen S.p.A., an Italian-Swiss biotechnology group specializing in targeted anti-cancer therapies based on tumor and vascular targeting technologies, focuses on developing innovative pharmaceuticals for high-mortality diseases using proprietary...
Philogen posts record 2025 profit on RayzeBio deal, plans dividend and R&D push
Mar 27, 2026
Philogen reported record 2025 results, with net profit surging to €229.7 million and revenue from contracts with customers jumping more than fourfold to €314.3 million, largely driven by a major upfront payment from a licensing deal wi...
Philogen Expands Treasury Share Buyback, Nears 0.87% of Share Capital Held
Mar 9, 2026
Philogen has provided an update on its ongoing treasury share buyback program, detailing that it repurchased 3,005 shares on Euronext Milan between 2 and 6 March 2026 at an average price of €20.9924, for a total outlay of €63,082.27. T...
Philogen Adds to Treasury Stock with Ongoing Share Buyback on Euronext Milan
Mar 2, 2026
Philogen has reported fresh progress in its ongoing share buyback programme, acquiring 1,503 shares on Euronext Milan between 23 and 27 February 2026 at an average price of €20.9081, for a total outlay of €31,424.85. Since the programm...
Philogen Expands Treasury Stock as Biotech Buyback Program Advances
Feb 9, 2026
Philogen S.p.A. has continued its share buyback program on the Euronext Milan market, repurchasing 31 treasury shares between 2 and 6 February 2026 at an average price of €20.90, for a total outlay of €647.90. These purchases form part...
Spouse of Philogen Chairman Sells 800 Shares in Insider Transaction Disclosure
Feb 5, 2026
Philogen S.p.A. disclosed that Anna Paola Tempesti, the spouse of Chairman of the Board Duccio Neri, sold a total of 800 Philogen ordinary shares on the Borsa Italiana’s MTA market on 13 June 2025. The trades, executed at a price of €2...
Philogen Increases Treasury Stock with New Tranche of Share Buybacks
Feb 2, 2026
Philogen S.p.A. has disclosed an update on its ongoing share buyback program, reporting the repurchase of 949 own shares between 26 and 30 January 2026 on Euronext Milan at an average price of €21.3147 per share, for a total outlay of €...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.